{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:15:44Z","timestamp":1780085744688,"version":"3.54.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.neulet.2019.134564","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:38:35Z","timestamp":1573645115000},"page":"134564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cerebrospinal fluid levels of alpha-synuclein, amyloid \u03b2, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson\u2019s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings"],"prefix":"10.1016","volume":"715","author":[{"given":"Takayuki","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Kikuchi-Takeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsutaka","family":"Okizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Hasebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2019.134564_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ane.12563","article-title":"The genetic background of Parkinson\u2019s disease: current progress and future prospects","volume":"134","author":"Kalinderi","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neulet.2019.134564_bib0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology."},{"key":"10.1016\/j.neulet.2019.134564_bib0015","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson\u2019s disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neulet.2019.134564_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain."},{"key":"10.1016\/j.neulet.2019.134564_bib0030","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1136\/jnnp.2009.197483","article-title":"Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"81","author":"Kasuga","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.neulet.2019.134564_bib0035","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","article-title":"Cerebrospinal fluid Tau\/\u03b1-synuclein ratio in Parkinson\u2019s disease and degenerative dementias","volume":"26","author":"Parnetti","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.055","article-title":"CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer\u2019s disease","volume":"1251","author":"Noguchi-Shinohara","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2019.134564_bib0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-2009-0955","article-title":"Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders","volume":"16","author":"Spies","year":"2009","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neulet.2019.134564_bib0050","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"\u00d6hrfelt","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2019.134564_bib0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson\u2019s disease","volume":"7","author":"Park","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081654","article-title":"The diagnostic value of CSF \u03b1-synuclein in the differential diagnosis of dementia with Lewy bodies vs. Normal subjects and patients with Alzheimer\u2019s disease","volume":"8","author":"Kapaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2019.134564_bib0065","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","article-title":"Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders","volume":"69","author":"Hall","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0070","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/WAD.0b013e31823899cc","article-title":"Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease","volume":"26","author":"Tateno","year":"2012","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0075","first-page":"1277","article-title":"Parkinson\u2019s Progression Markers Initiative. Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0080","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","article-title":"A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes","volume":"86","author":"Magdalinou","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.neulet.2019.134564_bib0085","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neulet.2019.134564_bib0090","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/mds.26036","article-title":"Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis","volume":"29","author":"Sako","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0095","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1017\/S1041610215000447","article-title":"Use of CSF \u03b1-synuclein in the differential diagnosis between Alzheimer\u2019s disease and other neurodegenerative disorders","volume":"27","author":"Wang","year":"2015","journal-title":"Int. Psychogeriatr."},{"key":"10.1016\/j.neulet.2019.134564_bib0100","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/mds.27110","article-title":"Diagnostic utility of cerebrospinal fluid \u03b1-synuclein in Parkinson\u2019s disease: a systematic review and meta-analysis","volume":"32","author":"Eusebi","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2217\/bmm.10.90","article-title":"Quantification of \u03b1-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies","volume":"4","author":"Mollenhauer","year":"2010","journal-title":"Biomark. Med."},{"key":"10.1016\/j.neulet.2019.134564_bib0110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3233\/JPD-150682","article-title":"Associations between cerebrospinal fluid biomarkers and cognition in early untreated parkinson\u2019s disease","volume":"5","author":"Skogseth","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.neulet.2019.134564_bib0115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","article-title":"Cerebrospinal fluid patterns and the risk of future dementia in early, incident parkinson disease","volume":"72","author":"B\u00e4ckstr\u00f6m","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0120","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.neurobiolaging.2014.07.043","article-title":"Correlation between decreased CSF \u03b1-synuclein and A\u03b2\u2081\u2212\u2084\u2082 in Parkinson disease","volume":"36","author":"Buddhala","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neulet.2019.134564_bib0125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2015.04.027","article-title":"Amyloid-\u03b2 and \u03b1-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson\u2019s disease","volume":"21","author":"Stav","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1212\/WNL.0000000000001098","article-title":"CSF biomarkers and clinical progression of Parkinson disease","volume":"84","author":"Hall","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2019.134564_bib0135","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12031-015-0647-x","article-title":"CSF \u03b2-Amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed parkinson disease","volume":"58","author":"Terrelonge","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neulet.2019.134564_bib0140","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s10072-017-3088-1","article-title":"Changes of cerebrospinal fluid A\u03b242, t-tau, and p-tau in Parkinson\u2019s disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis","volume":"38","author":"Hu","year":"2017","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.neulet.2019.134564_bib0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0175674","article-title":"Parkinson\u2019s Progression Markers Initiative (PPMI). Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease","volume":"12","author":"Caspell-Garcia","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.neulet.2019.134564_bib0150","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/mds.27001","article-title":"Tau\/\u03b1-synuclein ratio and inflammatory proteins in Parkinson\u2019s disease: an exploratory study","volume":"32","author":"Delgado-Alvarado","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0155","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-180390","article-title":"Brain amyloid contribution to cognitive dysfunction in early-stage parkinson\u2019s disease: the PPMI dataset","volume":"66","author":"Fiorenzato","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neulet.2019.134564_bib0160","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","article-title":"Second consensus statement on the diagnosis of multiple system atrophy","volume":"71","author":"Gilman","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neulet.2019.134564_bib0165","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0170","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neulet.2019.134564_bib0175","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"H\u00f6glinger","year":"2017","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0180","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12149-017-1209-9","article-title":"Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB","volume":"31","author":"Okizaki","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.neulet.2019.134564_bib0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.parkreldis.2008.05.001","article-title":"Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders","volume":"15","author":"Constantinescu","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0190","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1002\/mds.22895","article-title":"Differential pattern of brain-specific CSF proteins tau and amyloid-\u03b2 in Parkinsonian syndromes","volume":"25","author":"S\u00fcssmuth","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fneur.2012.00187","article-title":"Cerebrospinal fluid biomarker candidates for parkinsonian disorders","volume":"3","author":"Constantinescu","year":"2013","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neulet.2019.134564_bib0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.parkreldis.2013.09.003","article-title":"CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls","volume":"20","author":"Herbert","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neulet.2019.134564_bib0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nbd.2015.05.004","article-title":"Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative","volume":"80","author":"Laurens","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neulet.2019.134564_bib0210","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/14737175.2017.1392239","article-title":"Potential clinical utility of multiple system atrophy biomarkers","volume":"17","author":"Jellinger","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neulet.2019.134564_bib0215","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain."},{"key":"10.1016\/j.neulet.2019.134564_bib0220","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of \u03b1-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394019306676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394019306676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:33:35Z","timestamp":1759610015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394019306676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":44,"alternative-id":["S0304394019306676"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2019.134564","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid levels of alpha-synuclein, amyloid \u03b2, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson\u2019s disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2019.134564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"134564"}}